You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 255 No. 13, April 4, 1986 TABLE OF CONTENTS
  JAMA
  •  Online Features
  SPECIAL COMMUNICATIONS
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on Web of Science (20)
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Treatment of Uncomplicated Infections due to Neisseria gonorrhoeae

A Review of Clinical Efficacy and In Vitro Susceptibility Studies From 1982 Through 1985

Roselyn J. Rice, MD; Sumner E. Thompson, MD, MPH

JAMA. 1986;255(13):1739-1746.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

GONORRHEA remains the most frequently reported infectious disease in the United States. Antimicrobial resistance in the gonococcus continues to evolve, and coinfection with Chlamydia trachomatis is a serious problem. Therefore, the periodic review of current therapies for gonorrhea to ensure effective treatment must be a major objective of the National Gonorrhea Control Program in the United States.

In the past five years, the number of potentially useful antimicrobial agents for the treatment of gonococcal infections has proliferated: these include second- and third-generation cephalosporins, regimens combining the β-lactamase inhibitors clavulanic acid and sulbactam with penicillin and amoxicillin, and the quinolones.

This article reviews (1) recent trends in gonococcal antimicrobial resistance and in vitro susceptibility to established and experimental regimens; (2) coinfection due to C trachomatis and Neisseria gonorrhoeae within the past five years; (3) therapy for incubating syphilis and gonorrhea; (4) prophylaxis of sexual partners exposed to resistant organisms; and (5) . . . [Full Text PDF of this Article]


Author Affiliations

From the Division of Sexually Transmitted Diseases, Center for Prevention Services, Centers for Disease Control, Atlanta.


Footnotes

Reprint requests to Division of Sexually Transmitted Diseases, Technical Information Services, Centers for Disease Control, Atlanta, GA 30333 (Dr Rice).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1986 American Medical Association. All Rights Reserved.